News from amgen inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 28, 2014, 09:15 ET
Amgen Logo. (PRNewsFoto/Amgen)

Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol

Amgen (NASDAQ:AMGN) today announced that the Phase 3 YUKAWA-2 (StudY of LDL-Cholesterol Reduction Using a Monoclonal PCSK9 Antibody in Japanese...

Aug 28, 2014, 09:00 ET
Amgen Logo. (PRNewsFoto/Amgen)

Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA

Amgen (NASDAQ: AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for...

Aug 27, 2014, 09:15 ET
Amgen Logo. (PRNewsFoto/Amgen)

FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure

Amgen (NASDAQ: AMGN) today announced the U.S. Food and Drug Administration (FDA) has granted priority review designation for ivabradine for the...

Aug 18, 2014, 17:17 ET
Amgen Logo. (PRNewsFoto/Amgen)

Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis

 Amgen (NASDAQ:AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary...

Aug 13, 2014, 16:12 ET
Amgen Logo. (PRNewsFoto/Amgen)

Amgen Issues Voluntary Recall of Aranesp® (darbepoetin alfa) (500 mcg) Prefilled Syringes in Several Countries Outside of the United States Due to the Presence of Visible Particulates

 Amgen (NASDAQ:AMGN) initiated a voluntary recall on June 26, 2014 for nine packaged lots of Aranesp® (darbepoetin alfa) (500 mcg)...

Aug 13, 2014, 16:01 ET
Amgen Logo. (PRNewsFoto/Amgen)

Amgen Announces Top-Line Results From Phase 3 Focus Trial Of Kyprolis® In Patients With Relapsed And Advanced Refractory Multiple Myeloma

 Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that the Phase 3 clinical trial FOCUS (CarFilzOmib for...

Aug 04, 2014, 07:30 ET
Amgen Logo. (PRNewsFoto/Amgen)

Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In Patients With Relapsed Multiple Myeloma Met Primary Endpoint

 Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the...

Jul 29, 2014, 16:37 ET
Amgen Logo. (PRNewsFoto/Amgen)

Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37

Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2014. Key results include: - Total revenues increased 11...

Jul 25, 2014, 16:00 ET
Amgen Logo. (PRNewsFoto/Amgen)

Amgen Announces 2014 Third Quarter Dividend

Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the third quarter of 2014. The dividend...

Jul 24, 2014, 16:00 ET
Amgen Logo. (PRNewsFoto/Amgen)

Amgen Announces Webcast of 2014 Second Quarter Financial Results

Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Tuesday, July 29, 2014, after the close of the U.S....

Jul 17, 2014, 16:01 ET
Amgen Logo. (PRNewsFoto/Amgen)

Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis

 Amgen (NASDAQ:AMGN) today announced that a Phase 3 study evaluating AMG 416 (formerly known as velcalcetide) for the treatment of secondary...

Jul 01, 2014, 08:09 ET
Amgen Logo. (PRNewsFoto/Amgen)

Amgen Receives FDA Breakthrough Therapy Designation For Investigational BiTE® Antibody Blinatumomab In Acute Lymphoblastic Leukemia

 Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to...

Jun 16, 2014, 16:03 ET
Amgen Logo. (PRNewsFoto/Amgen)

Amgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer

Amgen (NASDAQ:AMGN) announced today that it will collaborate with the National Cancer Institute (NCI), part of the National Institutes of Health,...

Jun 11, 2014, 17:00 ET
Amgen Logo. (PRNewsFoto/Amgen)

Brodalumab Treatment Improved Clinical Signs And Symptoms In Phase 2 Psoriatic Arthritis Study Published In The New England Journal Of Medicine

Amgen (NASDAQ:AMGN) and AstraZeneca today announced that results from a Phase 2 study evaluating brodalumab in 168 patients with psoriatic...

Jun 09, 2014, 16:15 ET
Amgen Logo. (PRNewsFoto/Amgen)

Amgen Appoints David W. Meline Executive Vice President and Chief Financial Officer

 Amgen (NASDAQ:AMGN) today announced the appointment of David W. Meline as executive vice president and chief financial officer (CFO),...

Jun 06, 2014, 16:15 ET
Amgen Logo. (PRNewsFoto/Amgen)

Amgen To Present At The Goldman Sachs Global Healthcare Conference

 Amgen (NASDAQ:AMGN) will present at the Goldman Sachs Global Healthcare Conference at 1:20 p.m. PT on Wednesday, June 11, 2014, at the...

Jun 02, 2014, 07:44 ET
Amgen Logo. (PRNewsFoto/Amgen)

Amgen Presents New Data On Talimogene Laherparepvec As Single Agent And Combination Therapy In Metastatic Melanoma At ASCO

 Amgen (NASDAQ: AMGN) today announced new data from two key clinical trials that support the potential of talimogene laherparepvec, a novel,...

Jun 01, 2014, 10:11 ET
May 31, 2014, 08:00 ET
Amgen Logo. (PRNewsFoto/Amgen)

Amgen Highlights Phase 2 Results Of Vectibix® (panitumumab) Versus bevacizumab In Combination With FOLFOX In Patients With Wild-Type RAS (KRAS And NRAS) Metastatic Colorectal Cancer

Amgen (NASDAQ:AMGN) today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab...

May 30, 2014, 16:58 ET
Amgen Logo. (PRNewsFoto/Amgen)

Amgen To Present At The Jefferies 2014 Global Healthcare Conference

 Amgen (NASDAQ:AMGN) will present at the Jefferies 2014 Global Healthcare Conference at 11:30 a.m. ET on Wednesday, June 4, 2014, at the Grand...